Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Income from Continuing Operations (2016 - 2025)

Immucell (ICCC) has disclosed Income from Continuing Operations for 16 consecutive years, with 139749.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 80.08% year-over-year to 139749.0, compared with a TTM value of 2323670.0 through Sep 2025, up 160.97%, and an annual FY2024 reading of 2156629.0, up 62.65% over the prior year.
  • Income from Continuing Operations was 139749.0 for Q3 2025 at Immucell, down from 501881.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1446983.0 in Q1 2025 and bottomed at 2315053.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 457589.95, with a median of 441303.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations crashed 2349.8% in 2022, then skyrocketed 430.46% in 2025.
  • Year by year, Income from Continuing Operations stood at 74134.0 in 2021, then plummeted by 2349.8% to 1667866.0 in 2022, then surged by 31.66% to 1139831.0 in 2023, then skyrocketed by 145.14% to 514555.0 in 2024, then plummeted by 127.16% to 139749.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ICCC at 139749.0 in Q3 2025, 501881.0 in Q2 2025, and 1446983.0 in Q1 2025.